

Premium Hemp Joint 16, Pink Panther, High CBD

FARM BILL COMPLIANT



SAMPLE ID **442740**

SAMPLE NAME
Premium Hemp Joint 16, Pink Panther, High CBD

MATRIX
Pre-Roll

COLLECTED, RECEIVED 03/16/2022 17:02

MANUFACTURER INFO
Tk Queens LLC
1440 S State College Blvd Suite 5f
Anaheim, CA 92806

TOTAL CBD	14.71 %
TOTAL D9-THC	0.1174 %
TOTAL CANNABINOIDS	17.63 %

Indicates that the hemp product passes some of the strictest testing standards available for cannabis and hemp.





TOTAL THC: 13.00 mg/g (1.300 %)
TOTAL CBD: 147.1 mg/g (14.71 %)
TOTAL CANNABINOIDS: 176.3 mg/g (17.63 %)

UNIT OF MEASUREMENT: Milligrams per Gram(mg/g)

ANALYTE	RESULT	LOD	LLOQ	ANALYTE	RESULT	LOD	LLOQ
THCa	11.83 mg/g (1.183 %)	0.5000	1.0000	CBDa	142.6 mg/g (14.26 %)	0.5000	1.0000
D9THC	1.174 mg/g (0.1174 %)	0.5000	1.0000	CBD	4.538 mg/g (0.4538 %)	0.5000	1.0000
D8THC	ND	0.5000	1.0000	CBDv	ND	0.5000	1.0000
CBN	ND	0.5000	1.0000	CBCa	12.66 mg/g (1.266 %)	0.5000	1.0000
THCva	ND	0.5000	1.0000	CBC	<ll0q< th=""><th>0.5000</th><th>1.0000</th></ll0q<>	0.5000	1.0000
THCv	ND	0.5000	1.0000	CBGa	3.535 mg/g (0.3535 %)	0.5000	1.0000
ExoTHC	ND	0.5000	1.0000	CBG	ND	0.5000	1.0000
CBL	ND	0.5000	1.0000				

ADDITIONAL INFORMATION

 Method:
 SOP-TECH-001
 Sample Prepped:
 03/21/2022 11:21
 Sample Approved:
 03/21/2022 17:48

 Instrument:
 UPLC-DAD
 Sample Analyzed:
 03/21/2022 11:42
 Prep-Analytical Batch:
 36002-29762

This report applies to the sample investigated and is not necessarily indicative of the quality or condition of apparently identical or similar products. This report provides technical results for a specific sample and the report shall not be altered, modified, supplemented, or abstracted in any manner. Any violation of these conditions renders the report and its results void. Furthermore, warning indications for analytes reported as 'ND' or '<LLOQ' on this COA are from data collected outside our validated ISO 17025 methodologies, and are only reported at the request of the customer. All LQC samples required by state regulations (4 CCR section 15730) were performed and met the acceptance criteria.

THIS COA WAS REVIEWED AND APPROVED ON 03/21/2022 IN ACCORDANCE WITH REGULATORY REQUIREMENTS

Marc Gregerson, PhD Science Director